|
Delaware
|
33-0728374
|
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
|
incorporation)
|
Identification No.)
|
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1. Pursuant to the Dynavax 2004 Non-Employee Directors' Option Plan (the "Directors' Plan"), Dr. Cano was granted an initial non-qualified stock option to purchase 20,000 shares of Dynavax common stock, with an exercise price equal to the fair market value on the date of grant, vesting over four years in equal annual installments;
2. Pursuant to the Directors' Plan, Dr. Cano will automatically receive a non-qualified option to purchase an additional 10,000 shares of Dynavax common stock at each annual meeting of Dynavax's stockho lders (with respect to the first such grant, the option will be pro-rated such that the fraction of such 10,000 shares shall equal the fraction of the year that he serves until the 2010 annual meeting), with an exercise price equal to the fair market value on the date of grant, vesting on the first anniversary of the grant; and
3. Dr. Cano will receive an annual retainer of $20,000, payable in equal quarterly installments in arrears, $2,000 for each Board meeting attended in person and $500 for each Board meeting attended by telephone.
A copy of the press release relating to Dr. Cano's appointment is attached hereto as Exhibit 99.1.
|
Dynavax Technologies Corporation
|
||||||||
|
Date: November 05, 2009
|
By:
|
/s/ Jennifer Lew
|
||||||
|
Jennifer Lew
|
||||||||
|
Vice President, Finance
|
||||||||
|
Exhibit No.
|
Description
|
|
|
EX-99.1
|
Press Release, dated November 5, 2009, titled "Dynavax Appoints Francis R. Cano, Ph.D. to Board of Directors".
|
|
DYNAVAX DYNAVAX TECHNOLOGIES 2929 Seventh Street, Suite 100 Berkeley, CA 94710 |
Amy Figueroa
Investor Relations and Corporate Communications Phone: (510) 665-7211 Email: afigueroa@dynavax.com
DYNAVAX APPOINTS FRANCIS R. CANO, PH.D. TO BOARD OF DIRECTORS
BERKELEY, CA – November 5, 2009 – Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that Francis R. Cano, Ph.D. has been appointed to Dynavax’s Board of Directors effective November 3, 2009.
“A recognized scientific leader in vaccines and infectious diseases, Francis brings unique expertise and broad experience in research, development, and commercialization to Dynavax,” commented Arnold L. Oronsky, Ph.D., Chairman of the Board of Directors of Dynavax. “Francis will provide valuable perspective as Dynavax advances its plans for its Phase 3 hepatitis B vaccine and pipeline products.”
Dr. Cano is President and Founder of Cano Biotech Corp., a consulting firm focusing on the vaccine business. Previously, Dr. Cano was President and Chief Operating Officer for Aviron, which was later acquired by MedImmune in 2001. As a Co-Founder of Aviron, he completed two rounds of venture financing, a licensing agreement with SmithKline Biologicals, and in-licensed Flu-Mist influenza vaccine from the National Institutes of Health. For 21 years, Dr. Cano worked with the Lederle Laboratories Division of American Cyanamid, most recently as Vice President and General Manager of the Biologicals unit.
He earned a Ph.D. in Microbiology from Pennsylvania State University, served as a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in Microbiology and a B.S. in Biology from St. John's University.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV(TM), a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.
|
# # # |